SYHA136

**SYHA136** is a small molecule direct inhibitor of **coagulation Factor Xa (FXa)**, developed by **CSPC ZhongQi Pharmaceutical Technology** (a Shijiazhuang Group company) as an oral anticoagulant. It selectively inhibits FXa to prevent thrombin generation and clot formation, positioning it as a potential new oral anticoagulant (NOAC) for thrombotic disorders. A Phase I trial (NCT04036656) evaluated single ascending oral doses (0.5-50 mg) in healthy volunteers, assessing safety, pharmacokinetics (e.g., AUC, Cmax, t1/2), and pharmacodynamics (e.g., anti-FXa activity, clotting times like aPTT, TT, INR).[1][4][6][8]